Anaplastic Large Cell Lymphoma ALK-Negative — Specialist Treatment Access

Anaplastic large cell lymphoma (ALCL) is a type of T-cell lymphoma defined by large, pleomorphic tumour cells that uniformly express the CD30 antigen. It is divided into ALK-positive and ALK-negative subtypes based on whether the ALK gene is rearranged. ALK-positive ALCL is driven by the NPM1-ALK fusion gene (t(2;5)) and predominantly affects younger patients; it carries a more favourable prognosis. ALK-negative ALCL lacks ALK rearrangement, tends to occur in older adults, and generally follows a more aggressive course — though the molecular subtype (particularly DUSP22 rearrangement) can significantly modulate prognosis.

DUSP22 and TP63 are chromosomal rearrangements identified by FISH testing that subdivide ALK-negative ALCL into prognostically distinct molecular subgroups. DUSP22/IRF4 rearrangement (at chromosome 6p25.3) is found in approximately 30% of cases and is associated with a more favourable prognosis — similar to ALK-positive ALCL in some series. TP63 rearrangement is found in approximately 8% of cases and is associated with a markedly worse prognosis, with inferior outcomes even with autologous transplant consolidation. These results influence decisions about treatment intensity, transplant type (auto versus allo), and clinical trial enrolment. All patients with ALK-negative ALCL should have FISH testing for both rearrangements at diagnosis.

Brentuximab vedotin (BV, brand name Adcetris) is an antibody-drug conjugate — an anti-CD30 antibody linked to a cell-killing payload called MMAE. Because ALCL uniformly expresses high levels of CD30, BV selectively delivers its cytotoxic payload to the tumour cells. The ECHELON-2 Phase III trial demonstrated that BV combined with CHP chemotherapy (cyclophosphamide, doxorubicin, and prednisone — CHOP without vincristine) was superior to standard CHOP in CD30-positive PTCL including ALK-negative ALCL. BV-CHP is now the standard frontline regimen for fit patients with systemic ALK-negative ALCL at most expert centres.

Auto-SCT consolidation in first complete remission is recommended at most expert centres for intermediate- and high-risk ALK-negative ALCL, based on registry data showing improved remission duration with transplant. However, the decision is individualised based on molecular subtype, depth of response to BV-CHP, age, and fitness for transplant. In DUSP22-rearranged disease with deep metabolic remission, some specialist centres are evaluating whether auto-SCT can be safely deferred. In TP63-rearranged disease, auto-SCT may not be sufficient and allogeneic transplant is considered. These decisions are best made at a multidisciplinary PTCL transplant centre.

Breast implant-associated ALCL (BIA-ALCL) is a distinct ALK-negative, CD30-positive T-cell lymphoma that arises in the fibrous capsule surrounding textured breast implants, not from the breast tissue itself. It is a different disease from systemic ALCL and is managed very differently. The vast majority of BIA-ALCL cases are confined to the peri-implant space at diagnosis and are cured by complete surgical removal of the implant and its surrounding capsule (total capsulectomy). Only a minority present with lymph node or systemic spread requiring systemic therapy. Patients with textured implants should be aware of the signs (new unilateral breast swelling or seroma) and report them promptly for specialist evaluation.

Relapse after BV-CHP is a challenging situation that requires re-biopsy to confirm lymphoma and re-assess CD30 expression. BV monotherapy has demonstrated activity in the BV-naive relapse setting or may be used again after a sufficient interval. HDAC inhibitors (romidepsin), pralatrexate, and platinum-based salvage regimens (ICE, DHAP) are used with the goal of achieving remission and bridging to allogeneic stem cell transplantation in eligible patients. Clinical trial enrolment — including JAK inhibitor combinations, checkpoint inhibitors, and CAR-T programmes — is strongly encouraged for relapsed/refractory disease.

ALK-negative ALCL is not caused by a single inherited genetic mutation in the way that some cancers are hereditary. The chromosomal rearrangements that define molecular subtypes (DUSP22, TP63) are acquired somatic events — they occur in the tumour cells but are not passed down through families. Familial clustering of ALK-negative ALCL has not been described, and there is no known hereditary predisposition syndrome specifically associated with this entity. However, as with many T-cell lymphomas, JAK/STAT pathway mutations and other acquired oncogenic events contribute to lymphomagenesis in individual patients.

Response to BV-CHP is assessed by FDG PET-CT using Deauville criteria — typically at interim (after 2–4 cycles) and end-of-treatment. Complete metabolic remission (Deauville score 1–2) indicates a deep treatment response and is associated with better long-term outcomes. Partial metabolic response or PET-positive disease at end of treatment warrants further evaluation and treatment modification. Following transplant consolidation, PET-CT and clinical assessments are performed at regular intervals during surveillance. CD30 re-assessment is recommended at biopsy for relapse to confirm continued BV eligibility.

Yes. CancerFax supports patients with ALK-negative ALCL at all stages — from initial diagnosis and FISH subtype confirmation to BV-CHP access, transplant planning, and relapsed/refractory disease management. Our team reviews pathology reports and staging workups, coordinates specialist second opinions from expert haematopathologists and T-cell lymphoma oncologists, identifies clinical trial eligibility, and facilitates access to specialist PTCL programmes at leading centres in India, China, and internationally. Please share your medical reports through the CancerFax portal or contact our team to begin.